Am J Hum Genet:细胞信号传导介质β-catenin缺陷导致FEVR的视网膜血管病变!

2017-06-03 cuiguizhong MedSci原创

英国利兹大学医学研究所眼科与神经科学科教授Toomes C实验室在最新的一期Am J Hum Genet杂志上发表了他们近期一项重要研究成果:细胞信号传导介质β-catenin缺陷导致FEVR的视网膜血管病变!

英国利兹大学医学研究所眼科与神经科学科教授Toomes C实验室在最新的一期Am J Hum Genet杂志上发表了他们近期一项重要研究成果:细胞信号传导介质β-catenin缺陷导致FEVR的视网膜血管病变!

家族性渗出性玻璃体视网膜病变(FEVR)是以视网膜脉管系统发育异常为特征的遗传性视力缺陷。在FEVR中鉴定出的大多数突变位于四个基因中,这四个基因是编码受体复合物(FZD4,LRP5和TSPAN12)和控制血管生成的分子途径(Norrin-β-catenin信号通路)的配体(NDP)。然而,并不是所有FEVR患者体内都存在这些基因的突变,约有一半的患者在这些基因中没有突变,这表明需要进一步鉴定突变的基因仍有待。

Toomes C实验室发现了一种新的导致FEVR的突变基因,CTNNB1(编码β-catenin的基因)。在发表的文章中,实验团队在两个主要的FEVR家族中发现了杂合突变(c.2142_2157dup [p.His720 *]和c.2128C> T [p.Arg710Cys]),在一个病例中发现了新生突变(c.1434_1435insC [p.Glu479Argfs * 18])。之前有研究者报道,新生CTNNB1突变是导致综合征智力障碍(ID)和自闭症障碍的原因,也有很多研究指出体细胞突变与许多癌症相关。然而,在Toomes C的最新的研究中发现,遵循孟德尔遗传规律的CTNNB1突变可引起非综合征FEVR,而FEVR可能是综合征ID的一种表型。Toomes C的最新研究结果表明,需要进一步研究β-catenin信号在视网膜脉管系统发育中的作用,促进人们对家族性渗出性玻璃体视网膜病变(FEVR)机制的理解。

原文出处:

Panagiotou, E.S., et al., Defects in the Cell Signaling Mediator beta-Catenin Cause the Retinal Vascular Condition FEVR. Am J Hum Genet, 2017. 100(6): p. 960-968.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2017-06-17 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2018-05-14 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2018-03-22 circumcision
  5. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2017-06-05 zutt
  8. [GetPortalCommentsPageByObjectIdResponse(id=1644559, encodeId=3b7916445593b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 25 18:47:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733879, encodeId=eae51e338791b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jun 17 07:47:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048847, encodeId=0745204884ef5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon May 14 22:47:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7363, encryptionId=1b69e363bb, topicName=FEV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Mar 22 21:47:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686104, encodeId=a41e1686104d2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 25 06:47:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804940, encodeId=9dbb180494035, content=<a href='/topic/show?id=a6d1e7783af' target=_blank style='color:#2F92EE;'>#细胞信号传导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77783, encryptionId=a6d1e7783af, topicName=细胞信号传导)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sun Mar 04 15:47:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269881, encodeId=c182126988121, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391066, encodeId=8aa4139106636, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Jun 05 10:47:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]

相关资讯

全球“机器人眼科医生”中山眼科中心“看门诊”

AI(人工智能)机器人为你诊断眼病,你信得过吗?5月4日,记者从中山大学中山眼科中心了解到,该院研发了我国首个眼科人工智能诊断决策系统,只需要将先天性白内障患者眼睛的照片上传至云平台,通过AI机器人的深度分析和诊断,几分钟就可以出具诊断、风险评估和治疗方案。目前该AI平台已临床验证了超过300名患者。有关该成果的论文已经在国际一流医学杂志《自然》子刊上作为封面文章发表。中山眼科中心还开辟了全球首个

Ophthalmologica:糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人!

日本东京医科大学医学中心眼科系的Shimura M实验室在最新一期的Ophthalmologica上发表了他们近期的一项工作。他们测量了35例(37只眼)接受抗血管内皮生长因子(VEGF)治疗的糖尿病性黄斑水肿(DME)患者眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎性因子的水平。

山东省眼科医院与省红会开展“复明项目工程” 诊疗费免除

5月26日,山东省角膜捐献及白内障复明工程培训班暨济南市红十字会、山东省红十字眼库角膜捐献志愿服务培训班在山东省眼科医院14楼学术报告厅胜利召开。

Ophthalmology:在增生性玻璃体视网膜病变研究慢性释放地塞米松的作用--前瞻性、随机的临床对照试验

英国伦敦Moorfields眼科医院的Charteris DG教授实验室近期在Ophthalmology发表了他们的一项杰出工作。他们提出一个假设,地塞米松作为外源植入物,缓慢释放地塞米松可以提高患有增生性玻璃体视网膜病变(PVR)患者在玻璃体视网膜手术后的愈后效果。为了测试这一假设,他们设计了一个为期2年的,单中心,前瞻性,参与者和外科医生双盲随机对照临床试验(EudraCT No. 2011-

Ophthalmic Res: MicroRNA-200b在增生性糖尿病视网膜病变患者玻璃体中的表达显着增高!

埃及亚历山大大学医学部眼科系的Moftah RF实验室在最新的一期Ophthalmic Res杂志上发表了他们团队一项重要的工作,揭示了miRNA-200b和VEGF在PDR患者的玻璃体中的表达情况。

Invest Ophthalmol Vis Sci:PET可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征!

西班牙圣地亚哥德孔波斯特拉大学(CIMUS)眼科的González F团队近日在Invest Ophthalmol Vis Sci杂志上发表了他们近期的一项研究工作。文章指出,在研究玻璃体清除随时间的变化过程中,正电子发射断层扫描(PET)可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征。